BCR-ABL1 kinase: hunting an elusive target with new weapons

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib are standard treatments for BCR-ABL1-positive cancers.
• These TKIs function by blocking the ATP-binding pocket of the BCR-ABL1 kinase, thereby inhibiting its activity.

Discussion:

• A recent study in Cell by Grebien et al. introduces a novel therapeutic strategy targeting the BCR-ABL1 kinase.
• This new approach focuses on disrupting the SH2-kinase domain interface, distinct from the conventional ATP-binding site.

Key Insights:

• The SH2-kinase domain interface represents a previously underexplored vulnerability in BCR-ABL1 kinase.
• Targeting this interface offers a potential strategy to overcome resistance mechanisms associated with ATP-binding pocket inhibitors.

Outlook:

• Further investigation into the SH2-kinase domain interface could lead to the development of next-generation BCR-ABL1 inhibitors.
• This approach may hold promise for patients with resistant or refractory BCR-ABL1-driven malignancies.